Even biotech ETFs remain less bad than their broader market, investors should exercise selectivity among these funds. For example, IBB and BBH have been less bad due to substantial allocations to large-cap biotechs such as Amgen (NasdaqGS: AMGN) and Biogen (NasdaqGS: BIIB). Conversely, XBI, which as an equal weight ETF features ample small-cap exposure, is down 6.2% in the past month.

iShares Nasdaq Biotechnology ETF

Chart Courtesy: J. Beck Investments

ETF Trends editorial team contributed to this post.